Bayzed Health Launches HK IPO to Expand Cancer Care Services
China-based Bayzed Health Group Inc. (HKG: 2609), a private healthcare provider specializing in oncology, has...
TransThera Sciences Sets Hong Kong IPO at HKD13.15 Per Share
China-headquartered TransThera Sciences (Nanjing) Inc. is preparing for an initial public offering (IPO) of 15.281...
BeOne Medicines Wins FDA Approval for Brukinsa Tablet Across All Five Indications
China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that it has received...
Gene Solutions Partners with Topgen Biopharm to Advance Precision Oncology in Asia
Vietnam-based Gene Solutions, a provider of genetic tests and non-invasive prenatal testing (NIPT) for women’s...
Suzhou’s MEI Medical Secures RMB 100M Funding for ePTFE Innovation
Suzhou-based MEI Medical Technologies Co., Ltd., a medical device manufacturer specializing in peripheral vascular intervention,...
BMS Reports Positive POETYK PsA-1 Results for Sotyktu in Psoriatic Arthritis
US-based Bristol-Myers Squibb (BMS; NYSE: BMY) announced positive results from the pivotal Phase III POETYK...
Lilly Launches Mounjaro Multi-Dose Pen in China for Diabetes and Weight Management
US-based Eli Lilly & Co. (NYSE: LLY) announced the launch of Mounjaro (tirzepatide multi-dose prefilled...
XtalPi Acquires Liverpool ChiroChem to Boost AI-Driven Drug Discovery
Shenzhen-based XtalPi Holdings Limited (HKG: 2228), an AI-driven pharmaceutical company, announced the complete acquisition of...
Shandong Boan Partners with Shanghai Pharma for BA5101 Diabetes Drug
China-based Shandong Boan Biotechnology Co., Ltd (HKG: 6955) announced a strategic collaboration with Shanghai Pharmaceuticals...
GCCF and CTTQ Explore Collaboration to Expand Innovative Drug Access in Hong Kong
Dr. Cheng Kam-chung, Founder and Chairman of the Greater China Cancer Foundation (GCCF), led a...
ImmVira Commences Phase II Trial for MVR-T3011 in High-Risk NMIBC
Shenzhen-based ImmVira announced that it has administered the first patient dose in a global, multi-center...
Escugen Partners with SovranBio to Accelerate Development of Antibody-Drug Conjugates
Shanghai Escugen, a China-based clinical-stage company specializing in innovative antibody-drug conjugate (ADC) development, announced a...
Varian Medical Systems Secures NMPA Approval for Ethos 2.0 AI Radiotherapy Platform
US-based Varian Medical Systems (NYSE: VAR) announced that it has received marketing approval from China’s...
Novo Nordisk China Restructures to Form New Obesity and Diabetes Department
Danish pharmaceutical giant Novo Nordisk’s (NYSE: NVO) China unit announced an organizational restructuring, merging its...
Eli Lilly Partners with Juvena Therapeutics on Muscle Health AI Platform
US-based Eli Lilly & Co. (NYSE: LLY) announced a global licensing and multi-target research collaboration...
Daiichi Sankyo Launches Phase I Trial for Enhertu Subcutaneous Formulation
Japan-based Daiichi Sankyo (TYO: 4568) has registered a Phase I clinical trial on ClinicalTrials.gov for...
NMPA Issues Immediate Guidelines for NGS-Related IVD Reagent Classification
China’s National Medical Products Administration (NMPA) released the “Guidelines for Classification Definition of Next-Generation Sequencing...
China Updates Class 3 Hospital Accreditation Standards for 2025
Last month, China’s National Health Commission officially issued the Class 3 Hospital Accreditation Standards (2025...
Huadong Medicine Receives NMPA Approval for Phase III Trial of Roflumilast Foam
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that Its wholly-owned subsidiary Hangzhou Zhongmei Huadong...
China’s Sichuan Kelun-Biotech Wins BTD for Sac-TMT in Non-Squamous NSCLC
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that its core product Jiatailai (sacituzumab...